Pfizer Says Its COVID-19 Pill Can Cut Hospitalizations, Death Risk by 90%
Pfizer says its experimental pill for COVID-19 cut rates of hospitalization and death by nearly 90% among patients with mild-to-moderate infections.
The company announced Friday it will soon ask the U.S. Food and Drug Administration and international regulators to authorize its pill, which is taken twice a day for five days.
A similar pill from competitor Merck is currently under FDA review and was cleared Thursday by U.K. regulators.
Drugmakers around the world have been racing to develop an easy-to-use pill to blunt the effects of COVID-19. All therapies now authorized in the U.S. require an IV or injection.
(Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.)